Trial Profile
An exploratory, double-blind comparison of inspiratory capacity and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open label b.i.d. administration of formoterol
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jul 2017
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
- 15 Sep 2007 Results presented at ERS 2007 (1083888)
- 29 Jan 2007 New trial record.